Global Budesonide (BUD) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Budesonide (BUD) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product typesInjectable Suspension, inhaler and Inhalation Powder.
Budesonide (BUD) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Budesonide (BUD) market is projected to reach US$ 12110 million in 2034, increasing from US$ 8203 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2034. Demand from Respiratory Disease Treatment and Nose Disease Treatment are the major drivers for the industry.
North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.
The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Budesonide (BUD) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Cosmo Pharmaceuticals
Teva
Mylan
Sandoz
Dr. Falk Pharma
Chiesi Farmaceutici
Orion
Cipla
Synmosa Biopharma
Lunan Better Pharmaceutical
Shanghai Sine Promod Pharmaceutical
Segment by Type
Nasal Spray
Inhaler
Pill
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Budesonide (BUD) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Budesonide (BUD), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Budesonide (BUD) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Budesonide (BUD) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Budesonide (BUD) introduction, etc. Budesonide (BUD) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Budesonide (BUD) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Budesonide (BUD) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Budesonide (BUD) market is projected to reach US$ 12110 million in 2034, increasing from US$ 8203 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2034. Demand from Respiratory Disease Treatment and Nose Disease Treatment are the major drivers for the industry.
North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.
The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Budesonide (BUD) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Cosmo Pharmaceuticals
Teva
Mylan
Sandoz
Dr. Falk Pharma
Chiesi Farmaceutici
Orion
Cipla
Synmosa Biopharma
Lunan Better Pharmaceutical
Shanghai Sine Promod Pharmaceutical
Segment by Type
Nasal Spray
Inhaler
Pill
Segment by Application
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Budesonide (BUD) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Budesonide (BUD), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Budesonide (BUD) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Budesonide (BUD) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Budesonide (BUD) introduction, etc. Budesonide (BUD) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Budesonide (BUD) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices